Treatment of Insomnia and Glucose Metabolism
Information source: University of Chicago
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Sleep; Insomnia; Insulin Resistance
Intervention: Eszopiclone (Drug); Placebo (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Chicago Official(s) and/or principal investigator(s): Plamen D Penev, MD, PhD, Principal Investigator, Affiliation: University of Chicago
Summary
Available data suggest that obtaining adequate sleep is associated with a better ability of
the body to use carbohydrates as a source of energy and a lower risk of developing diabetes.
The sleeping pill, Eszopiclone (Lunesta), has been approved by the Food and Drug
Administration for the treatment of people who complain of trouble falling or staying
asleep. This study will examine the hypothesis that the use of Eszopiclone (Lunesta) to
improve the sleep of people with insomnia may also improve the use of sugar in their body.
Clinical Details
Official title: Double-blind Placebo-controlled Study of the Effects of Eszopiclone on Glucose Tolerance, Insulin Secretion, and Insulin Action in Adults With Chronic Insomnia
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Primary outcome: plasma glucose level at the 120-minute time point of a 75g oral glucose tolerance test
Secondary outcome: first phase insulin secretion in response to intravenous glucoseindex of insulin sensitivity
Detailed description:
Study participants will complete a set of oral and intravenous glucose (sugar) tolerance
tests, which will be performed on two separate occasions in random order: once after a week
of treatment with Eszopiclone (Lunesta) and once again after a week of receiving placebo.
Eligibility
Minimum age: 35 Years.
Maximum age: 64 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- age between 35 and 64
- must have long-standing trouble falling or staying asleep
- BMI between 22 and 34 kg/m2
Exclusion Criteria:
- sleep apnea or other sleep disorder other than insomnia
- diagnosis of diabetes requiring treatment with pills or insulin
- smoking
- night or shift work
- presence of a medical condition that can disrupt sleep
- women only: irregular menstrual periods or pregnancy
- use of medications/compounds that can disrupt sleep
Locations and Contacts
University of Chicago, Chicago, Illinois 60637, United States
Additional Information
Starting date: April 2008
Last updated: March 28, 2012
|